Analytical Data
-
Gene name
MAP4K4
- Application
-
Alternative Names
MAP4K4; mitogen-activated protein kinase kinase kinase kinase 4; FLH21957; hepatocyte progenitor kinase like/germinal center kinase like kinase; HGK; HPK/GCK like kinase; NIK
-
Species
Human
-
Source
Baculovirus
-
Tag
N-GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95819-1
-
Expression Region
A2-E328
-
Protein Length
Partial
-
Molecular Weight
64.1 KDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAP4K4 (Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4) is a member of the MAP4K family that plays a crucial role in various cellular processes, including cell growth, differentiation, and stress response. The research on MAP4K4 has garnered attention due to its involvement in several pathological conditions, such as cancer, obesity, and autoimmune diseases. It functions as a signaling mediator in the MAPK cascade, influencing downstream pathways that regulate cell survival and apoptosis. Dysregulation of MAP4K4 has been implicated in tumorigenesis, making it a potential biomarker and therapeutic target for cancer treatment. Recent studies have explored the molecular mechanisms underlying MAP4K4's role in promoting oncogenic pathways, as well as its interaction with other signaling molecules. Furthermore, the development of specific inhibitors targeting MAP4K4 offers promising avenues for therapeutic strategies. Understanding the intricate functions and regulatory mechanisms of MAP4K4 may provide insights into novel interventions for diseases associated with its dysregulation, paving the way for advancements in targeted therapies and personalized medicine.
